You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb411593 |
---|---|
Category | Antibodies |
Description | Human monoclonal antibody to CD22 |
Species/Host | Human |
Clonality | Monoclonal |
Clone Number | hL22 (Epratuzumab) |
Tested applications | Blocking, FC, IP |
Reactivity | Human, Primate |
Isotype | IgG1 |
Immunogen | This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5–10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010). |
Concentration | 1 mg/ml |
Purity | Purified |
Conjugation | Unconjugated |
Target | CD22 |
UniProt ID | P20273 |
Storage | Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C. |
Buffer/Preservatives | PBS with 0.02% Proclin 300. |
Alternative names | Leu14; B-cell receptor CD22; B-lymphocyte cell adh Read more... |
Note | For research use only |
Application notes | Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010). |
Expiration Date | 12 months from date of receipt. |
ELISA, FACS, IHC-P | |
Human | |
Mouse | |
Monoclonal | |
Unconjugated |
ELISA, IHC-P | |
Human | |
Mouse | |
Monoclonal | |
Unconjugated |
Filter by Rating